NCT02170181
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Drug Category: Radiation Therapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients can have up to 6 sites of active extracranial disease (outside of the brain) with a maximum of 7 cm diameter
Exclusions:
https://ClinicalTrials.gov/show/NCT02170181